|Table of Contents|

The research development of PD-1/PD-L1 signaling axis regulated by lactate in tumor microenvironment

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 15
Page:
2944-2948
Research Field:
Publishing date:

Info

Title:
The research development of PD-1/PD-L1 signaling axis regulated by lactate in tumor microenvironment
Author(s):
GE Yan; CHEN Zhihong
Affiliated People's Hospital of Jiangsu University,Jiangsu Zhenjiang 212002,China.
Keywords:
lactate; immune checkpoint blockade; tumor microenvironment; tumor-associated macrophages; tumor-associated neutrophils; regulatory T cells
PACS:
R73
DOI:
10.3969/j.issn.1672-4992.2023.15.034
Abstract:
Tumor cells consume glucose and release excessive lactate due to the Warburg effect.Locally lactate buildup in the tumor microenvironment results from special tumor vasculature,which directly suppresses functions of immune cells.High concentrations of lactate can also act as a signaling molecular to drive tumor development through recruitment of cells that are associated with immunosuppression and regulation of immune checkpoint axis.This review will focus on regulation and mechanisms of lactate action on PD-1/PD-L1 axis of tumor and tumor-associated stromal cells.In the meantime,we realize that the application of lactate dehydrogenase,the critical lactate biosynthetic enzyme,in PD-1 and PD-L1 immune checkpoint blocking therapy,which may make targeted LDH a new strategy to improve the efficacy of PD-1/PD-L1 blockade therapy.

References:

［1］AKINLEYE A,RASOOL Z.Immune checkpoint inhibitors of PD-L1 as cancer therapeutics［J］.J Hematol Oncol,2019,12(1):1-13.
［2］HERBST RS,GARON EB,KIM DW,et al.Long-term outcomes and retreatment among patients with previously treated,programmed death ligand 1 positive,advanced non small-cell lung cancer in the KEYNOTE-010 study［J］.J Clin Oncol,2020,38(14):1580-1590.
［3］CARLINO MS,LARKIN J,LONG GV.Immune checkpoint inhibitors in melanoma［J］.Lancet,2021,398(10304):1002-1014.
［4］SHITARA K,AJANI JA,MOEHLER M,et al.Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer［J］.Nature,2022,603(7903):942-948.
［5］HEGDE PS,CHEN DS.Top 10 challenges in cancer immunotherapy［J］.Immunity,2020,52(1):17-35.
［6］BADER JE,VOSS K,RATHMELL JC.Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy［J］.Mol Cell,2020,78(6):1019-1033.
［7］HIAM-GALVEZ KJ,ALLEN BM,SPITZER MH.Systemic immunity in cancer［J］.Nat Rev Cancer,2021,21(6):345-359.
［8］PAVLOVA NN,THOMPSON CB.The emerging hallmarks of cancer metabolism［J］.Cell Metabolism,2016,23(1):27-47.
［9］WANG ZH,PENG WB,ZHANG P,et al.Lactate in the tumour microenvironment:From immune modulation to therapy［J］.EBioMedicine,2021,73:103627.
［10］GHESQUIERE B,WONG BW,KUCHNIO A,et al.Metabolism of stromal and immune cells in health and disease［J］.Nature,2014,511(7508):167-176.
［11］MARTINEZ-REYES I,CHANDEL NS.Cancer metabolism:looking forward［J］.Nature Reviews Cancer,2021,21(10):669-680.
［12］XIA LZ,OYANG L,LIN JG,et al.The cancer metabolic reprogramming and immune response［J］.Mol Cancer,2021,20(1):28.
［13］BROWN TP,GANAPATHY V.Lactate/GPR81 signaling and proton motive force in cancer:Role in angiogenesis,immune escape,nutrition,and Warburg phenomenon［J］.Pharmacol Ther,2020,206:107451.
［14］LIU C,JIN Y,FAN ZM.The mechanism of Warburg effect-induced chemoresistance in cancer［J］.Front Oncol,2021,11:698023.
［15］WANG JX,CHOI SY,NIU XJ,et al.Lactic acid and an acidic tumor microenvironment suppress anticancer immunity［J］.Int J Mol Sci,2020,21(21)：8363.
［16］CERTO M,TSAI CH,PUCINO V,et al.Lactate modulation of immune responses in inflammatory versus tumour microenvironments［J］.Nat Rev Immunol,2021,21(3):151-161.
［17］MU XM,SHI W,XU Y,et al.Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer［J］.Cell Cycle,2018,17(4):428-438.
［18］CHEN PW,ZUO H,XIONG H,et al.Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis［J］.Proc Natl Acad Sci USA,2017,114(3):580-585.
［19］SHAN T,CHEN S,CHEN X,et al.M2-TAM subsets altered by lactic acid promote T-cell apoptosis through the PDL1/PD1 pathway［J］.Oncol Rep,2020,44(5):1885-1894.
［20］URATA K,KAJIHARA I,MIYAUCHI H,et al.The Warburg effect and tumour immune microenvironment in extramammary Paget's disease:overexpression of lactate dehydrogenase A correlates with immune resistance［J］.J Eur Acad Dermatol Venereol,2020,34(8):1715-1721.
［21］MORRISSEY SM,ZHANG F,DING C,et al.Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming［J］.Cell Metab,2021,33(10):2040-2058.
［22］KWANTWI LB,WANG SJ,ZHANG WJ,et al.Tumor-associated neutrophils activated by tumor-derived CCL20（C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1（PD-L1) in breast cancer［J］.Bioengineered,2021,12(1):6996-7006.
［23］DENG HJ,KAN A,LYU N,et al.Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma［J］.J Immunother Cancer,2021,9(6)：e002305.
［24］WANG LW,LIU YH,DAI YT,et al.Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment［J］.Gut,2022,2022:1-14.
［25］OHKURA N,SAKAGUCHI S.Transcriptional and epigenetic basis of Treg cell development and function:its genetic anomalies or variations in autoimmune diseases［J］.Cell Res,2020,30(6):465-474.
［26］MIN H,KIM W,HONG S,et al.Differentiation and homeostasis of effector Treg cells are regulated by inositol polyphosphates modulating Ca(2+) influx［J］.Proc Natl Acad Sci USA,2022,119(27):e2121520119.
［27］WATSON MJ,VIGNALI PD,MULLETT SJ,et al.Metabolic support of tumour-infiltrating regulatory T cells by lactic acid［J］.Nature,2021,591(7851):645-651.
［28］KUMAGAI S,KOYAMA S,ITAHASHI K,et al.Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments［J］.Cancer Cell,2022,40(2):201-218.
［29］DUAN XX,XIE Y,YU J,et al.MCT4/lactate promotes PD-L1 glycosylation in triple-negative breast cancer cells［J］.J Oncol,2022,2022:3659714.
［30］FENG J,YANG H,ZHANG Y,et al.Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells［J］.Oncogene,2017,36(42):5829-5839.
［31］BROWN TP,BHATTACHARJEE P,RAMACHANDRAN S,et al.The lactate receptor GPR81 promotes breast cancer growth via a paracrine mechanism involving antigen-presenting cells in the tumor microenvironment［J］.Oncogene,2020,39(16):3292-3304.
［32］XIE H,HANAI JI,REN JG,et al.Targeting lactate dehydrogenase-a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells［J］.Cell Metab,2014,19(5):795-809.
［33］SETH P,CSIZMADIA E,HEDBLOM A,et al.Deletion of lactate dehydrogenase-A in myeloid cells triggers antitumor immunity［J］.Cancer Res,2017,77(13):3632-3643.
［34］DANESHMANDI S,WEGIEL B,SETH P.Blockade of lactate dehydrogenase-A（LDH-A) improves efficacy of anti-programmed cell death-1（PD-1) therapy in melanoma［J］.Cancers（Basel),2019,11(4)：450.
［35］ZHANG YJ,LI J,WANG B,et al.LDH-A negatively regulates dMMR in colorectal cancer［J］.Cancer Sci,2021,112(8):3050-3063.
［36］TANG BX,YAN XQ,SHENG XN,et al.Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients［J］.Journal of Hematology & Oncology,2019,12(1):7.
［37］DONG TY,LIU ZL,XUAN QJ,et al.Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis［J］.Sci Rep,2017,7(1):6069.
［38］DIEM S,KASENDA B,SPAIN L,et al.Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma［J］.Br J Cancer,2016,114(3):256-261.
［39］OYA Y,YOSHIDA T,KURODA H,et al.Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer［J］.Oncotarget,2017,8(61):103117-103128.
［40］PRELAJ A,FERRARA R,REBUZZI S E,et al.A prognostic score for immunotherapy in advanced non-small-cell lung cancer:A validation cohort［J］.Cancers（Basel),2019,11(12)：1954.
［41］HEIDELBERGER V,GOLDWASSER F,KRAMKIMEL N,et al.Clinical parameters associated with anti-programmed death-1（PD-1) inhibitors-induced tumor response in melanoma patients［J］.Invest New Drugs,2017,35(6):842-847.
［42］ZHAO XM,WU XH,YU H,et al.Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors［J］.Front Immunol,2022,13:1003581.
［43］INDINI A,DI GUARDO L,CIMMINIELLO C,et al.Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma［J］.Tumori,2019,105(6):465-473.
［44］CHEN L,ZHAO RH,SUN H,et al.The prognostic value of gastric immune prognostic index in gastric cancer patients treated with PD-1/PD-L1 inhibitors［J］.Front Pharmacol,2022,13:833584.
［45］KORNEPATI AV,VADLAMUDI RK,CURIEL TJ.Programmed death ligand 1 signals in cancer cells［J］.Nat Rev Cancer,2022,22(3):174-189.
［46］ZHANG D,TANG ZY,HUANG H,et al.Metabolic regulation of gene expression by histone lactylation［J］.Nature,2019,574(7779):575-580.

Memo

Memo:
National Natural Science Foundation of China（No.81972313）;国家自然科学基金面上项目（编号：81972313）
Last Update: 2023-06-30